Pompey, France, July 19, 2012 - Novasep, a leading supplier of manufacturing solutions to the life sciences industries, announces today a three million euro investment to expand its Highly Potent API (HPAPI) manufacturing capabilities at its Le Mans (France) facility. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies.
Pompey, France, April 23, 2011 – Novasep, a leading supplier of purification and production solutions for the life sciences industry, announces two new managerial appointments. Jean-Claude Romain becomes the group’s Corporate Quality Director and a member of Novasep’s executive committee, while Alain Lamproye joins Novasep Process, the company’s biomolecules division, as Director of Novasep Belgium and becomes a member of Novasep Process’s management committee.
Cerenis Therapeutics to present manufacturing data for this biopharmaceutical against atherosclerotic cardiovascular disease at BioProcess International (BPI) Conference in Prague (Czech Republic), April 18, 2012.
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia.
A strongly improved balance sheet, new shareholders and an entrepreneurial management to support the group’s development going forward.
New protein A media boosts productivity in monoclonal and polyclonal antibody capture, lowers costs.
All Novasep Synthesis sites pass FDA inspections in last three years.
Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds. Joint technical showcase presentation at Informex, Charlotte, NC, USA, Feb 7, Booth: 1987
Joint project will offer a cost-effective, environmentally friendly process to produce betaine, an animal feed ingredient in short supply.
Novasep’s role in scaling up this patented process helped Nutritis close a EUR 13.5M financing round and acquire a fructose unit exclusively for fruit processing.